(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/226135 A1

(51) International Patent Classification:
A61K 31/517 (2006.01) *A61P 25/28* (2006.01)
A61P 25/16 (2006.01) *C07D 471/04* (2006.01)

(21) International Application Number:
PCT/US2021/030719

(22) International Filing Date:
04 May 2021 (04.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/019,768 04 May 2020 (04.05.2020) US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand oaks, California 91320-1799 (US). **VIGIL NEUROSCIENCE, INC.** [US/US]; 400 Technology Square, 10th Floor, Cambridge, California 02138 (US).

(72) Inventors: **CZABANIUK, Lara C.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **HOPPER, Timothy**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **HOUZE, Jonathan B.**; c/o Vigil Neuroscience, Inc., 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). **RESCOURIO, Gwenaella**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **SANTORA, Vincent**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WANG, Haoxuan**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WHITE, Ryan D.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WONG, Alice R.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WU, Yongwei**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title:** HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE



(I)

(57) **Abstract:** The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

WO 2021/226135 A1